CNS Delivery Via Adsorptive Transcytosis
Open accessAbstract
Adsorptive-mediated transcytosis (AMT) provides a means for brain delivery of medicines across the blood-brain barrier (BBB). The BBB is readily equipped for the AMT process: it provides both the potential for binding and uptake of cationic molecules to the luminal surface of endothelial cells, and then for exocytosis at the abluminal surface. The transcytotic pathways present at the BBB and its morphological and enzymatic properties provide the means for movement of the molecules through the endothelial cytoplasm. AMT-based drug delivery to the brain was performed using cationic proteins and cell-penetrating peptides (CPPs). Protein cationization using either synthetic or natural polyamines is discussed and some examples of diamine/polyamine modified proteins that cross BBB are described. Two main families of CPPs belonging to the Tat-derived peptides and Syn-B vectors have been extensively used in CPP vector-mediated strategies allowing delivery of a large variety of small molecules as well as proteins across cell membranes in vitro and the BBB in vivo. CPP strategy suffers from several limitations such as toxicity and immunogenicity--like the cationization strategy--as well as the instability of peptide vectors in biological media. The review concludes by stressing the need to improve the understanding of AMT mechanisms at BBB and the effectiveness of cationized proteins and CPP-vectorized proteins as neurotherapeutics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanoparticles can be tailored to deliver therapeutic agents precisely to affected brain regions, enabling highly targeted interventions.
“Beyond their ability to cross the BBB, NPs can be tailored to deliver therapeutic agents precisely to affected brain regions, enabling highly targeted interventions [195].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [195]
The citation lists haven’t been fetched yet
References 135 · Cited by 676
- Authors
- Hervé, F., Ghinea, N., & Scherrmann, J.-M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Corresponding author
- Hervé, Françoise
- ORCID
- Ghinea, Nicolae
- Venue
- The AAPS Journal
- Published
- 2008-08-26
- Volume
- 10
- Issue
- 3
- Pages
- 455-472
- ISSN
- 1550-7416 (ISSN-L)
- PMC
- PMC2761699
- OpenAlex
- W2036821782
- Cited by
- 676
- References
- 135
- Citations by year
- 2026: 44 · 2025: 66 · 2024: 60 · 2023: 57 · 2022: 61 · 2021: 49 · 2020: 51 · 2019: 38 · 2018: 38 · 2017: 41 · 2016: 28 · 2015: 41 · 2014: 24 · 2013: 27 · 2012: 19
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The AAPS Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- blood-brain barrier, brain drug delivery, cell-penetrating peptides, cationic proteins, transcytosis, neurotherapeutics
- MeSH terms
- Adsorption, Animals, Biological Transport, Blood-Brain Barrier, Cations, Pharmaceutical Preparations, Endocytosis, Humans, Peptides, Proteins, Drug Delivery Systems, Endothelial Cells, Electrophysiological Phenomena
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review